Dateline City:
KENILWORTH, N.J.
Results from KEYNOTE-024, which Studied KEYTRUDA Compared to Chemotherapy in Patients with High Levels of PD-L1 Expression, and KEYNOTE-021G, which Studied KEYTRUDA in Combination with Chemotherapy Compared to Chemotherapy Alone in Patients Regardless of PD-L1 Expression, to be Presented
Comprehensive Data from Mercks Industry-Leading Immuno-Oncology Clinical Development Program to be Presented, with New Data in 12 Cancers
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that extensive data on KEYTRUDA
(pembrolizumab), the companys anti-PD-1 therapy, have been accepted for
presentation at the European Society for Medical Oncology (ESMO) 2016
Congress in Copenhagen, Denmark, Oct. 7 11. In total, findings from 30
studies in 12 cancers from Mercks industry-leading clinical development
program for KEYTRUDA both as monotherapy and in combination will be
presented at this years ESMO.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558Kim Hamilton, 908-740-1863orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more